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We present the first reported case of left ventricular assist device (LVAD) pump 
thrombosis in the setting of the coronavirus pandemic. We describe the clinical 
features of the case which helped to differentiate coronavirus disease 19 (COVID-
19) from LVAD pump thrombosis. The patient is 56-year-old female supported by 
destination LVAD therapy. She was originally implanted with a HeartMate II device 
in 2015 and underwent two pump exchanges in 2017 and 2019 for pump 
thrombosis, despite medication adherence. Shortly after routine lab work revealed 
near doubling of her lactate dehydrogenase (LDH) levels, she tested positive for 
COVID-19. She then developed power spikes and symptomatic heart failure, 
which prompted hospital admission. An initial computed tomography (CT) scan 
showed bilateral ground glass opacities, but repeat testing was negative for 
COVID-19. Her LVAD pump thrombosis was treated with aspirin, unfractionated 
heparin, and cangrelor, which was guided by thromboelastogram. Over several 
weeks, her LDH returned to baseline, and she was transitioned from cangrelor to 
ticagrelor and from heparin to warfarin. A repeat CT scan after several days of IV 
diuresis showed resolution of the ground glass opacities.  
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Background 
The coronavirus disease 2019 (COVID-19) pandemic creates unique challenges, as 
it complicates the diagnosis of common medical problems. In general, infection is 
known to frequently precede pump thrombosis in patients on left ventricular assist 
device (LVAD) support,1 but the potential role of coronavirus in precipitating pump 
thrombosis is unknown. We present the case of pump thrombosis in a patient with 
COVID-19 infection. 
 
Case Series Description 
A 56-year-old female with history of ischemic cardiomyopathy and morbid obesity 
received a HeartMate II (HMII) device (Abbott Laboratories, Abbott Park, IL) in 2015 
as destination therapy. Her course was complicated by two episodes of pump 
thrombosis at 23 months and 55 months post-implantation. Each episode required 
a pump exchange. 
During a routine laboratory check in 2020, it was noted that her lactate 
dehydrogenase (LDH) increased to 1727 Units/Liter (baseline LDH in 800-900s 
U/L). Since she had no other symptoms, the test was repeated 2 days later, and her 
LDH returned to baseline level of 802 U/L at that time. Within a week, she developed 
a fever, mild cough, myalgias, fatigue and tested positive for COVID-19. Since her 
symptoms were mild, she was advised to self-quarantine at home without any 
additional medications. During this time, the patient’s international normalized ratio 
(INR) remained within therapeutic range (2-3). After 14 days of quarantine, the 
patients LDH showed a persistent elevation at 1722 U/L. Analysis of the LVAD’s log 
file captured a single elevated power of 10 W about 10 days after patient was 
symptomatic with COVID-19 infection (Figure 1). At this point she was transferred 
to our center for further evaluation. 
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Upon admission, the physical exam was significant for a multi-tonal hum on 
auscultation, instead of the monotonic hum of HMII. The patient was afebrile, an 
oxygenation saturation of 94% on room air, a mean arterial pressure of 70 mmHg 
and a heart rate of 80 beats per minute. The following day, the patient became 
progressively more dyspneic with activity, had crackles on auscultation, and was 
hypoxic requiring oxygen. She was tested for COVID-19 by 
nasopharyngeal/oropharyngeal swab upon admission and again a few days later, 
both tests returned negative. The differential diagnosis at this point was pump 
thrombosis with heart failure versus worsening of the COVID-19 infection. The 
computed tomography (CT) angiography of the chest revealed patchy bilateral 
ground glass opacities throughout both lungs in a pattern concerning for COVID-19 
(Figures 2) or acute pulmonary edema. There was no thrombus in the inflow and 
outflow cannulas, raising concern for thrombosis in the pump itself. An 
echocardiogram showed a dilated left ventricle with end diastolic diameter of 5.8 cm 
and a dilated hypokinetic right ventricle. 
 
Figure 2. Computed tomography (CT) 
angiogram of the chest that depicts bilateral 
ground glass opacities. A) Frontal plane 
view B) Transverse plane view 
 
She was started on diuretics, milrinone, and heparin. Her dual antiplatelet regimen 
of aspirin (81 mg daily) and dipyridamole (75 mg three times daily) was continued. 
Thromboelastography (TEG) was suggestive of inadequate inhibition of platelets; 
hence, dipyridamole therapy was discontinued and cangrelor was initiated at a dose 
of 0.75 mcg/kg/min. 
With the combination of cangrelor and heparin, both the patient’s LDH and free 
hemoglobin trended down (Table 1). There was marked clinical improvement, and 
she was able to be weaned off diuretics and inotropic therapy by post-admission 
days 7 and 10, respectively. As clinical improvement was seen along with an 
improving LDH, cangrelor was transitioned to ticagrelor. A loading dose of ticagrelor 
was administered just prior to discontinuation of the cangrelor drip,   
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ADP - adenosine phosphate; MA - maximal amplitude; AA - arachidonic acid; LY30 - lysis at 30 minutes 
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followed by standard dosing of 90mg twice daily, replacing dipyridamole therapy. 
Warfarin was reinitiated at this time with the heparin drip continuing until the INR 
reached a target goal of 2.5-3.5. 
Figure 3. Transverse plane 
computed tomography angiogram 
chest after several days of diuresis 








Her condition improved, and she was ambulating well on room air. A repeat CT scan 
of the chest showed marked improvement of the patient’s bilateral ground glass 
opacities (Figure 3). The repeat echocardiogram showed a left ventricular end 
diastolic diameter of 4.9 cm and improved right heart function (Figure 4). A right 
heart catheterization was performed after hemodynamic stabilization showed a right 
atrial pressure of 6/3 mmHg and a mean pulmonary capillary wedge pressure of 6 
mmHg. Prior to discharge, the LDH was at baseline (607 U/L), free hemoglobin was 
2 mg/dL, and LVAD function was stable. TEG values while on the cangrelor infusion 
showed a more inhibited adenosine diphosphate arm compared to the TEG on 
admission. The patient was discharged home on warfarin (INR goals remained at 
2.5-3.5), ticagrelor (90 mg twice daily), and aspirin (81 mg daily).  
 
Figure 4. Echocardiogram upon presentation with LV dilatation. (Left panel). The 
echocardiogram after treatment of pump thrombosis (right panel). Both are in the 
parasternal long axis.  
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Discussion 
Pump thrombosis is a complication of LVAD implantation, affecting approximately 
5% of patients.2 It can present with clinically significant hemolysis, device alarms, 
left heart failure, and cardiogenic shock. Our patient had symptoms of fatigue, 
shortness of breath, hypoxia, dry cough, elevated LDH, and bilateral ground glass 
opacities in the setting of a recently positive COVID-19 test. All of these symptoms 
could be seen in both pump thrombosis and COVID-19 infection. T Ai et al. 
reported on a series of patients with an initially negative PCR test showed signs 
with COVID-19 on CT and subsequently became PCR positive.3 Thus, the 
negative PCR test upon admission did not rule out the possibility of an active 
COVID-19 infection. 
An LDH elevation is common in patients with COVID-19, and multiple retrospective 
analyses have shown a correlation between the degree of LDH elevation and 
outcome.4,5 Zhou et al. found that survivors of COVID-19 had a modest elevation 
of LDH, with an average value of 253 U/L, whereas non-survivors had an average 
of 521 U/L, ranging as high as 669 U/L.5 In a case series of 1099 patients, Guan et 
al. reported that among patients with LDH levels of greater than 250 U/L, 70.5% 
met the primary endpoint, which was a composite of intensive care unit (ICU) 
admission, mechanical ventilation, or death, compared to 39% of patients with a 
lower LDH.5 At the same time, LDH is the principal laboratory marker used to 
diagnose LVAD thrombosis. Pump thrombosis is generally suspected in HMII 
patients when the LDH level is greater than 600 U/L.  
The presence of ground glass opacities is another non-specific symptom. 
However, ground glass opacities have been reported to be among the most 
common radiologic findings in COVID-19, occurring in about half of patients;1,4-6 
they are also commonly seen in pulmonary edema. Cell-free hemoglobin 
elevations have also been shown to occur and predict poor outcomes in sepsis in 
non-LVAD patients.7 
In general, infection is an inflammatory event that can lead to a systemic 
hypercoagulable state, increasing the incidence of LVAD pump thrombosis. Many 
studies have shown that infection increases the risk of thrombotic complications of 
LVAD.1,8 This risk is seen within six weeks of a major infection.8 Our patient had a 
prior history of pump thrombosis; however, we suspected the current episode was 
triggered by the preceding COVID-19 infection. In retrospect, the COVID-19 
infection had likely resolved by the time she was hospitalized for the thrombotic 
event. 
Coagulopathy is a widely reported phenomenon in COVID-19, with high rates of 
venous and arterial thrombus formation.9,10 Klok et al. reviewed 184 ICU patients 
with COVID-19 and found that 35% of them had pulmonary embolism and 3.8% 
had arterial thrombotic events.9 Similarly, Merkler et al. reported a stroke rate of 
1.6% in COVID-19 patients presenting to the ED.11 There are emerging case 
reports of patients in their 30s with COVID-19-induced strokes.12 Indeed, our 
patient’s LDH nearly doubled eight days prior to the COVID-19 diagnosis, 
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suggesting the virus may have exacerbated or even precipitated the pump 
thrombus.  
In our analysis, the most helpful clinical clues to the eventual diagnosis of pump 
thrombosis in the setting of recent COVID-19 diagnosis were the degree of LDH 
elevation and the power spikes. LDH is rarely reported in excess of 600 U/L, even 
in high mortality cases from COVID-19. Given the acute surge in this patient to a 
peak value of 2287 U/L, we felt this was better explained by pump thrombosis, and 
that her COVID-19 had likely resolved by this point. Resolution of the ground glass 
opacities after diuresis (Figure 3) further supported pump thrombosis and not 
ongoing COVID-19. 
Medical management of pump thrombosis typically includes heparin monotherapy, 
direct thrombin inhibitors, thrombolytic agents, and/or glycoprotein IIb/IIIa 
inhibitors. The use of escalated therapies has been more successful than heparin 
alone in a number of cases; however, there is also a higher rate of bleeding seen 
with these agents.13 Cangrelor is a reversible P2Y12 inhibitor that is structurally 
and functionally similar to the more commonly used oral P2Y12 inhibitor, 
ticagrelor. Cangrelor rapidly blocks adenosine diphosphoate-mediated platelet 
aggregation and has a very quick onset of action with a short half-life. Our center 
has utilized cangrelor in combination with heparin for suspected pump thrombosis 
and have reported successful outcomes in at least two patients.14 In combination 
with other markers (i.e., LDH, pump parameters), our center has utilized TEG-
directed decision making to guide antiplatelet therapies for our LVAD patients. 
Although use of cangrelor at our center is rare and has not been directly compared 
to alternative agents, it has shown potential over previously described strategies in 
lowering LDH in suspected pump thrombosis while possibly providing a lower 
bleeding risk. 
In summary, this is the first case of pump thrombosis reported in a LVAD patient 
after COVID-19 infection. Our case is also unique in that we were able to medically 
manage the thrombosis with the combination of cangrelor and heparin. Earlier, 
Singh et al. proposed a registry of COVID-19 infection in LVAD population.15 We 
agree that such registry is needed for defining the cardiovascular effects in this 
special LVAD patient population. 
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